26th week of 2009 patent applcation highlights part 51 |
Patent application number | Title | Published |
20090163492 | Substituted Oxindole Derivatives, Drugs Containing Said Derivatives and the Use Thereof - The invention relates to novel oxindol derivative of general formula (I), wherein substituents R | 2009-06-25 |
20090163493 | Benzene, Pyridine, and Pyridazine Derivatives -
Disclosed are compounds and pharmaceutically acceptable salts of Formula I
| 2009-06-25 |
20090163494 | PROTEIN KINASE INHIBITORS - This invention relates to selenophene compounds of formula (I) shown below: | 2009-06-25 |
20090163495 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES - There are provided according to the invention, novel compounds of formula (I) | 2009-06-25 |
20090163496 | ANTIBACTERIAL AGENTS - Antibacterial compounds of formula I are provided: | 2009-06-25 |
20090163497 | Compounds Useful as Antagonists of CCR2 -
The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R | 2009-06-25 |
20090163498 | Aryl Sulfonamides - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2009-06-25 |
20090163499 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists - Compounds of the formula I: | 2009-06-25 |
20090163500 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS - The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds. | 2009-06-25 |
20090163501 | Aurora kinase modulators and method of use - The present invention relates to chemical compounds having a general formula I | 2009-06-25 |
20090163502 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists - Compounds of the formula I: | 2009-06-25 |
20090163503 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer. | 2009-06-25 |
20090163504 | Method for healing a wound using a phosphodiesterase type five inhibitor - A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as a phosphodiesterase type five inhibitor and pharmaceutically acceptable salts thereof. | 2009-06-25 |
20090163505 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS - The present invention relates to certain novel compounds of Formula (I): | 2009-06-25 |
20090163506 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain - Certain compounds of formula (I), | 2009-06-25 |
20090163507 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS - Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided. | 2009-06-25 |
20090163508 | AMIDE COMPOUND - An object of the present invention is to provide a novel fused-ring compound which has a FAAH inhibitory effect and is useful as an analgesic. | 2009-06-25 |
20090163509 | Method for healing a wound using an alpha-adrenergic antagonist - A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as an alpha-adrenergic antagonist and pharmaceutically acceptable salts thereof. | 2009-06-25 |
20090163510 | Methods of Identifying and Treating Individuals Exhibiting Mutant SRC Kinase Polypeptides - The invention described herein relates to mutant SRC kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant SRC kinase proteins. | 2009-06-25 |
20090163511 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same - Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 2009-06-25 |
20090163512 | Spiroindolinone Derivatives - There are provided compounds of the formula | 2009-06-25 |
20090163513 | PROCESS FOR ZIPRASIDONE USING NOVEL INTERMEDIATES - The present invention relates to a novel process for the preparation of high purity ziprasidone and pharmaceutically acceptable acid addition salts of ziprasidone; and solvates and hydrates thereof using novel intermediates and a purification method for ziprasidone and pharmaceutically acceptable acid addition salts of ziprasidone; and solvates and hydrates thereof. | 2009-06-25 |
20090163514 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF - The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep. | 2009-06-25 |
20090163515 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes - The present invention relates to a compound and a group of compounds which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS. The compounds can be used in screening programmes against protein kinases. The invention also provides methods for making compounds and libraries that include these compounds. | 2009-06-25 |
20090163516 | CARBOXAMIDES FOR CONTROLLING UNDESIRED MICRO-ORGANISMS IN PLANT PROTECTION - Novel carboxamides of the formula (I) | 2009-06-25 |
20090163517 | BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES - This invention is concerned with compounds of the formula | 2009-06-25 |
20090163518 | Novel Compounds - The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. | 2009-06-25 |
20090163519 | DOSING REGIMEN ASSOCIATED WITH LONG ACTING INJECTABLE PALIPERIDONE ESTERS - The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations. | 2009-06-25 |
20090163520 | MNK1 or MNK2 Inhibitors - The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 2009-06-25 |
20090163521 | Novel Pyrazolopyrimidinone Derivatives - The present invention relates to novel pyrazolopyrimidinones of the general formula (I), their derivatives, their analogs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrazolopyrimidinones derivatives of the general formula (I). | 2009-06-25 |
20090163522 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same - The invention relates to derivatives of pyrido[2,3-d]pyrimidine, to the preparation thereof, and to the therapeutic application of the same. | 2009-06-25 |
20090163523 | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor - The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination. | 2009-06-25 |
20090163524 | Novel Protein Kinase B Inhibitors - 060 - The invention relates to a novel group of compounds of Formula (I) or salts thereof: | 2009-06-25 |
20090163525 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY - The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 2009-06-25 |
20090163526 | Process for the Preparation of an Anti Microbial Extract from Leaves of the Plant Callistemon Rigidus - A process for the preparation of an antimicrobial extract from leaves of the plant | 2009-06-25 |
20090163527 | Spiropiperidines for use as tryptase inhibitors - The present invention is directed to a compound of Formula (I): | 2009-06-25 |
20090163528 | Pharmaceutical composition having analgesic effects - The pharmaceutical compositions having analgesic effect referred to in this invention are composed of the aconitine ingredients as the active medical ingredients and other acceptable auxiliary ingredients. The active medical ingredients shall at least include the fuziline compound of Formula (I). The drugs exert desirable analgesic effect with low toxicity. They can be made into commonly used oral preparations, injectable preparations and/or external preparations, including ointments, suppositories lotions, medicinal dressings, etc. | 2009-06-25 |
20090163529 | IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES - The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods. | 2009-06-25 |
20090163530 | FAST DISSOLVING ORALLY CONSUMABLE FILMS - Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed. | 2009-06-25 |
20090163532 | Aqueous Gel Formulations Containing Immune Response Modifiers - Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided. | 2009-06-25 |
20090163533 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases - Pyrazolo[3,4-c] ring compounds of Formula (I), e.g., pyrazolo[3,4-c]pyridines, pyrazolo[3,4-c]quinolines, 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and pyrazolo[3,4-c]naphthyridines, substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-06-25 |
20090163534 | Indolizine Derivatives - Compounds of formula (I) are ligands of the CRTH2 receptor and are useful in the treatment of respiratory disease: Formula (I) wherein R | 2009-06-25 |
20090163535 | Substituted Heteroarylalkanoic Acids - Disclosed are substituted heteroarylalkanoic acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis. | 2009-06-25 |
20090163536 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION - Methionyl tRNA synthetase inhibitors (MetRS) are provided for use in therapy as antibacterial agents in | 2009-06-25 |
20090163537 | Thienopyridinone Compounds and Methods of Treatment - The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included. | 2009-06-25 |
20090163538 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer - Compounds of formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity. | 2009-06-25 |
20090163539 | ENANTIOMER OF TENATOPRAZOLE AND THE USE THEREOF IN THERAPY - This invention relates to optically active substances of tenatoprazole, (+) and (−) -5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent. | 2009-06-25 |
20090163540 | Quinine Sulfate Polymorphs, Processes of Preparing, Compositions and Uses Thereof - Disclosed are new quinine sulfate polymorphs, methods of making the polymorphs as well as formulations prepared therefrom and uses thereof. | 2009-06-25 |
20090163541 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, ITS PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYLCHOLINE - The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor. | 2009-06-25 |
20090163542 | 5-ht7 receptor antagonists - The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders. | 2009-06-25 |
20090163543 | Histone Deacetylase Inhibitors and Methods of Use Thereof - One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention. | 2009-06-25 |
20090163544 | Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting - This invention relates to the treatment or prevention of nausea and/or vomiting by the administration of a NK-3 receptor antagonist. | 2009-06-25 |
20090163545 | Method For Altering The Lifespan Of Eukaryotic Organisms - A method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay. | 2009-06-25 |
20090163546 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS - Provided herein are compounds of the formula (I): | 2009-06-25 |
20090163547 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS -
The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds of formula (I) show affinity for 5-HT | 2009-06-25 |
20090163548 | Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases - Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2009-06-25 |
20090163549 | Pharmaceutical Composition Comprising an Amide Derivative - The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene ring or an optionally substituted 6-membered heteroaromatic ring containing N atom, a dashed line means existence or absence of a bond, n is 1 or 2, R | 2009-06-25 |
20090163550 | RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy. | 2009-06-25 |
20090163551 | Compositions and Methods for Treating Diseases - This invention relates to methods for treating, preventing and/or managing gastric injury, e.g., NSAID-induced gastric injury in a subject including administering to the subject tegaserod, alone or in combination with a proton pump inhibitor. Also provided are compositions and kits for use in methods of the invention. | 2009-06-25 |
20090163552 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES - This invention relates to novel carboxyl- or hydroxyl-substituted benzimidazole derivatives of formula (I) | 2009-06-25 |
20090163553 | BENZIMIDAZOLE COMPOUND CRYSTAL - A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent. | 2009-06-25 |
20090163554 | Use of CNI-OD Formulations for Controlling White Fly - Method of controlling eggs and nymphal stages of whitefly by the spray application of oil-based suspension concentrates containing at least one insecticide from the neonicotinyl series, at least one penetrant from the alcohol ethoxylate series, at least one vegetable oil, at least one nonionic surfactant and, if appropriate one or more additives. | 2009-06-25 |
20090163555 | SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES - Novel pyroglutamic acid derivatives (I), wherein R | 2009-06-25 |
20090163556 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS - The present invention relates to glycinamide derivatives of formula I, | 2009-06-25 |
20090163557 | Cannabinergic Lipid Ligands - One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect. | 2009-06-25 |
20090163558 | Substituted Methyl Aryl or Heteroaryl Amide Compounds - This invention provides a compound of the formula (I): | 2009-06-25 |
20090163559 | Estrogen receptor modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate. | 2009-06-25 |
20090163560 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES - A compound having a structure | 2009-06-25 |
20090163561 | AMORPHOUS METAXALONE AND AMORPHOUS DISPERSIONS THEREOF - The present invention provides various amorphous forms of the compound metaxalone (I), such as solid amorphous metaxalone and amorphous dispersions comprising metaxalone. The present invention further provides pharmaceutical compositions comprising these amorphous forms, and methods of their preparation. The present invention additionally provides methods of treating painful conditions (e.g., such as painful musculoskeletal conditions) comprising administering a therapeutically effective amount of any one of these amorphous forms to a subject in need thereof. | 2009-06-25 |
20090163562 | ORAL COMPOSITION COMPRISING 3-[5-[4-(CYCLOPENTYLOXY) -2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BENZISOXAZOL-6- YL)METHOXY]PHENYL]PROPIONIC ACID OR SALT THEREOF - An oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone is advantageous as an oral medication composition (1) which can be produced without requiring new manufacturing equipment; (2) which can be produced with simple steps; (3) which maintains stable solubility even with changes in the pH of the gastrointestinal tract and of which gastrointestinal tract absorption is improved. | 2009-06-25 |
20090163563 | Phorboxazole Compounds and Methods of Their Preparation - Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division. | 2009-06-25 |
20090163564 | Translational Dysfunction Based Therapeutics - Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eIF4E. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer. | 2009-06-25 |
20090163565 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof - Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain. | 2009-06-25 |
20090163566 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex - This invention relates to novel imidazole derivatives of the general formula (I): pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA | 2009-06-25 |
20090163567 | GERMICIDE COMPOSITION FOR AGRICULTURAL AND GARDENING APPLICATIONS AND METHOD FOR CONTROLLING PLANT DISEASE - It is to provide a composition having stable and high fungicidal effects against cultivated crops infected with plant diseases. | 2009-06-25 |
20090163568 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 2009-06-25 |
20090163569 | PROCESS FOR THE PRODUCTION OF AMIDES - The present invention relates to a process for the preparation of compounds of formula (I) wherein R | 2009-06-25 |
20090163570 | BLADDER CANCER TREATMENT AND METHODS - Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments. | 2009-06-25 |
20090163571 | PHARMACEUTICAL FOR USE IN THE TREATMENT OF URETEROLITHIASIS - The present invention provides pharmaceutical compositions useful for relieving pain caused by ureteral calculi, facilitating exclusion of ureteral calculi or the like. That is, the present invention provides a pharmaceutical composition for the treatment of ureteral lithiasis, which comprises as an active ingredient an indoline derivative represented by the following general formula (I) or a salt thereof. In the formula, R represents saturated or unsaturated aliphatic acyl which may have a substituent; hydroxyalkyl; aliphatic acyloxyalkyl; lower alkyl which has as a substituent lower alkoxy, carboxy, lower alkoxycarbonyl, aryl-substituted lower alkoxycarbonyl, carbamoyl, mono or di(lower alkyl)-substituted carbamoyl or cyano; optionally substituted aromatic acyl; furoyl or pyridylcarbonyl; R | 2009-06-25 |
20090163572 | Cooling Compounds - A method of providing a cooling sensation to the skin or the mucous membranes of the body, comprising the application thereto of at least one compound of the Formula I | 2009-06-25 |
20090163573 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEIN ACCRETION IN SKELETAL MUSCLE - A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and an effective amount of glutamine or derivative of glutamine, wherein the ingredients act substantially simultaneously to increase protein synthesis and inhibit protein degradation in skeletal muscle, via enhanced expression of heat shock proteins in cells, particularly heat shock protein 72. A method of same is also provided. | 2009-06-25 |
20090163574 | Stable Pharmaceutical Composition Containing Docetaxel and a Method of Manufacturing the Same - The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same. | 2009-06-25 |
20090163575 | SOLVENT SYSTEMS FOR POUR-ON FORMULATIONS FOR COMBATING PARASITES - This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep. | 2009-06-25 |
20090163576 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R | 2009-06-25 |
20090163577 | METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS - The cytotoxic natural product gambogic acid (GA) competes for BH3 peptide binding sites on several anti-apoptotic members of the Bcl-2 family of proteins and neutralizes the ability of these proteins to suppress release of apoptogenic proteins from isolated mitochondria. Structure-function analysis of GA using analogs suggested a general correlation between BH3 competition and cytoxicity activity. Compositions and methods are provided for using GA and its derivatives for treating cancer and for discovering other compounds that are useful for treating cancer through their interaction with Bcl-2-family proteins. | 2009-06-25 |
20090163578 | NOVEL MODIFICATION OF IMMUNOMODULATORY PROTEIN - Methods of inhibiting annexin I induced apoptosis by contacting a cell population containing a TRPM7/ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase. | 2009-06-25 |
20090163579 | Novel use of nutraceutical compositions - The use of at least one component selected from the group consisting of EGCG, hydroxytyrosol, resveratrol and derivatives, metabolites or analogues thereof in the manufacture of a nutraceutical composition for the prevention and treatment of muscle wasting leading to muscle loss, atrophy and other associated muscle disorders in animals, in particular mammals including humans. | 2009-06-25 |
20090163580 | Anti-aging composition containing resveratrol and method of administration - Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption. | 2009-06-25 |
20090163581 | Pharmaceutical Products for Treating Neoplastic Disease and Inflammation - Disclosed in certain embodiments is a pharmaceutical formulation and a functional food comprising a pharmaceutical ingredient comprising an active agent combination comprising flavonoids and tocotrienols in a ratio of about 75:25 to about 95:5 and at least one pharmaceutically acceptable excipient and methods to treat neoplastic diseases and inflammation. | 2009-06-25 |
20090163582 | Stable Pesticide Concentrates and End-Use Emulsions - Pesticide concentrates are provided containing an emulsifier that is an EPA list 4 inert and is a polyglycerol fatty acid ester, a sorbitan fatty acid ester or a combination thereof, a pesticide and a solvent that is either a EPA list 3 inert of acetyl ester, EPA list 4 inert of a methyl fatty ester, an acetyltributyl citrate, white mineral oil or a combination thereof. The pesticide can be a water-insoluble synthetic pyrethroid, natural pyrethrum, channel blocking insecticide, acetylcholinesterase inhibitor, oxadiazine, organophosphate, neonicotinoid insecticide, thiamethoxam, imidacloprid, acetamiprid, thiacloprid, clothianidin, nitenpyran, insect growth regulator, juvenile hormone mimic, fermentation insecticide, plant oil insecticide acaracide, miticide, fungicide, herbicide and combinations thereof. The pesticide concentrate is diluted with a hydrocarbon solvent, a white mineral oil or a combination thereof and mixed with water. A corrosion inhibitor is added to form a stable water-in-oil emulsion in conjunction with a propellant to make a ready-to-use aerosol for home, garden and public health pest control. | 2009-06-25 |
20090163583 | Process and an Apparatus for Producing Episesamin-Rich Compositions - To provide a process and an apparatus by means of which a composition that contains episesamin in a concentration greater than 50 wt % on the basis of the sum weight of sesamin and episesamin can be produced conveniently and at high yield. | 2009-06-25 |
20090163584 | THERAPEUTIC AGENT FOR RENAL FAILURE - A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I | 2009-06-25 |
20090163585 | Carbosulfane-Based Pesticidal Compositions, Process for Preparing Same, Process for Controlling Insects/Mites/Nematodes, and Use of Said Compositions - The present invention relates to pesticidal compositions comprising 2,3-dihydro-2,2-dimethylbenzofuran-7-yl(dibutylaminothio)methylcarbamate, namely benzofuranyl methylcarbamate, commonly known as carbosulfane, of structural formula (I). The present invention deals more particularly with compositions comprising this active compound at a high concentration, which makes it the most economical product for sale, more stable during storage and more effective in small quantities, and it may be further combined with one or more inerts. The present invention further discloses a process for preparing said compositions and a process for controlling insects/mites/nematode. The applications for these formulations include the treatment of seeds and leaves. In the latter case, in addition to the diluting agent, a mixture of anionic and non-ionic surfactants have been included in the formulation, so that the solution will become self-emulsifying upon being added to water. | 2009-06-25 |
20090163586 | Bis-(Sulfonylamino) Derivatives in Therapy 205 - The invention provides compounds of formula (I) | 2009-06-25 |
20090163587 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS - Ester prodrugs of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics, wherein the phorbol compounds are derivatized with a -x-o-c(o)-R′ group linked to the 6-carbon of the phorbol residue. | 2009-06-25 |
20090163588 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 2009-06-25 |
20090163589 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 2009-06-25 |
20090163590 | PROCESS FOR PRODUCING REFINED AVOCADO OIL RICH IN TRIGLYCERIDES, AND OIL OBTAINABLE BY SAID PROCESS - The present invention concerns a process for producing refined avocado oil rich in triglycerides. The invention also pertains to refined avocado oil rich in triglycerides obtainable by said process. Advantageously, the refined avocado oil of the invention contains a sterols-enriched unsaponifiable fraction. Advantageously, the refined avocado oil of the invention is substantially free of acetogenins and furanic lipids. The invention also concerns compositions containing said oil. The invention also pertains to such compositions for use as a medication, as a dermatological agent, as a cosmetic agent, or as a nutriceutical, for human or animal use. | 2009-06-25 |
20090163591 | USE OF SUGAR PHOSPHATES, SUGAR PHOSPHATE ANALOGS, AMINO ACIDS AND/OR AMINO ACID ANALOGS FOR MODULATING THE GLUCOLYSIS-ENZYME COMPLEX, THE MALATE ASPARATE SHUTTLE AND/OR THE TRANSAMINASES - The invention relates to methods for the treatment of tumors and/or for immune suppression and/or sepsis by modulating the association of the glycolysis enzyme complex/M2-PK and/or by inhibition of transaminases and/or separation of the binding of the malate dehydrogenase to p36 comprising administering a pharmaceutical composition comprising a substance selected from the group consisting of amino acids, amino acid analogs, sugar phosphates, sugar phosphate analogs, and mixtures of said substances. | 2009-06-25 |
20090163592 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex - The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements. | 2009-06-25 |